Alentis Therapeutics

Focus: Alentis Therapeutics is a Swiss biotech company focused on monoclonal antibody development targeting oncology, gastroenterology, and nephrology indications. The company operates as a clinical-stage pipeline player with no approved products or commercial revenue.

Oncology Gastroenterology Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Alentis Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Alentis Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ALE.C04

Head and Neck Cancer

Phase 1/2

Clinical Trials (1)

NCT06054477Study of ALE.C04 in Patients With Head and Neck Cancer

Phase 1/2

Help build intelligence for Alentis Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline of 4 monoclonal antibody programs across high-value indications (oncology, liver fibrosis, head/neck cancer, lung cancer) with active clinical trials
Swiss biotech base provides access to strong European biotech ecosystem and regulatory relationships with EMA
Opportunity to contribute to early-stage clinical development with potential for significant upside if programs advance

Watch Out For

Pre-revenue stage with zero active job postings signals company may not be actively expanding or facing hiring constraints
No Phase 3 programs in pipeline creates 3-5 year timeline before potential near-term regulatory milestones or inflection points
Limited publicly available data on funding, employee count, and financial position creates visibility gaps on company stability and runway

Generated by Claude from Alentis Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ALE.P02

Squamous Non-small-cell Lung Cancer

Phase 1/2

Clinical Trials (1)

NCT06747585A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Phase 1/2

ALE.P03

Advanced or Metastatic Solid Tumors (CLDN1+)

Phase 1/2

Clinical Trials (1)

NCT07169734A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Phase 1/2